Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03084471 · ClinicalTrials.gov registry record · Phase 3
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 867
- Enrollment target
NCT03084471 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 867 participants.
The verdict
NCT03084471, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 867 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
Interventions
- BIOLOGICAL MEDI4736 (Durvalumab)
- BIOLOGICAL MEDI4736 (Durvalumab) + Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2017-06-05 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03084471
The ClinicalTrials.gov registry entry for NCT03084471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 867 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 (Durvalumab) is the first listed.
NCT03084471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03084471 about?
NCT03084471 is a clinical study titled "An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.". To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
What is the current status of trial NCT03084471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 867 participants. The study started on 2017-06-05. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT03084471?
The interventions under investigation include: MEDI4736 (Durvalumab) (BIOLOGICAL), MEDI4736 (Durvalumab) + Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03084471?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.